Beyond mAbs with TandAbs With enhanced efficacy due to a bispecific mode of action and an excellent safety profile partly due to the absence of an Fc region, TandAbs represent a strong front runner in the race to develop alternatives to first-generation antibody therapeutics. Uwe Reusch and Stefan Knackmuss at Affimed Therapeutics AG (June 2011)
|